Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25002324 | 0.78 | CYP2D6 (0.34) | POLBLMNAMAPTCYP2D6 | |
| SCHEMBL23065753 | 0.78 | CYP2D6 (0.34) | POLBLMNAMAPTF10CYP2D6 | |
| SCHEMBL19601333 | 0.66 | ALDH1A1 (0.37) | POLBLMNAMAPT | |
| SCHEMBL23065706 | 0.65 | CYP4F2 (0.32) | — | |
| SCHEMBL7635527 | 0.65 | CYP19A1 (0.32) | — | |
| SCHEMBL23065708 | 0.64 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL23065412 | 0.64 | — | — | |
| SCHEMBL25002256 | 0.64 | OPRM1 (0.32) | — | |
| SCHEMBL23065415 | 0.63 | MEN1 (0.38) | LMNAMAPT | |
| SCHEMBL23065709 | 0.63 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | UNM RAINFOREST INNOVATIONS | 2023-02-09 | — | — | US | disclosed |
| WO-2021041107-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 | UNM RAINFOREST INNOVATIONS (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | GPER1, GPR35, GPR34 | POLB 1160/4885LMNA 2989/4885MAPT 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.